Correspondence | Published:

Reply to: Technical concerns about immunoprecipitation of methylated fetal DNA for noninvasive trisomy 21 diagnosis

Nature Medicine volume 18, pages 13281329 (2012) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    , , , & Nat. Med. 18, 1327–1328 (2012).

  2. 2.

    et al. Nat. Med. 17, 510–513 (2011).

  3. 3.

    et al. Prenat. Diagn. 10.1002/pd.3947 (26 July 2012).

  4. 4.

    et al. Proc. Natl. Acad. Sci. USA 105, 16266–16271 (2008).

  5. 5.

    et al. Proc. Natl. Acad. Sci. USA 105, 20458–20463 (2008).

Download references

Author information


  1. The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.

    • Philippos C Patsalis


  1. Search for Philippos C Patsalis in:

Competing interests

P.C.P. has filed a Patent Cooperation Treaty patent application (application no. PCT/IB2011/000217) for the MeDIP real-time quantitative PCR–based NIPD approach. The patent is now owned by NIPD Genetics Ltd. P.C.P. is a consultant with and holds equities in this company.

Corresponding author

Correspondence to Philippos C Patsalis.

About this article

Publication history



Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing